Abstract: The present invention relates to means and devices for electro-filtration of molecules. The membranes comprise N-acryloyl-tris(hydroxymethyl)aminomethane (NAT) covalently linked to a support. The invention further encompasses compositions comprising an isoelectric buffer covalently bound to N-acryloyl-tris(hydroxymethyl)aminomethane (NAT). In particular, the present invention relates to membranes and devices allowing an isoelectric filtration of molecules in solution.

Abstract: A method of sreening for compounds useful for the treatment of SSDs comprising contacting a test compound with a y-synuclein polypeptide and detecting interactions of the test compounds with said polypeptide or a nucleotide sequence encoding y-synuclein for the diagnosing of SSDs or susceptibility to SSDs, a kit useful for diagnosing SSDs or susceptibility to a SSDs, and a transgenic animal useful for the study of SSDs.

Abstract: Disclosed are polypeptide analogues of human C5a which are C5a receptor antagonists that exhibit substantially no analphylatoxin or agonist activity, and derivatives of the analogues, and dimeric forms of the analogues or derivatives. DNA molecules encoding the polypeptides and methods of making the analogues are also provided. Pharmaceutical formulations containing a C5a analogue, are used therapeutically in the treatment of C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an event which causes inflammation or aggravates an existing inflammatory condition, respectively. Further disclosed are antibodies specific to the C5a analogues, derivatives thereof, and dimers of the analogues and derivatives which exhibit substantially no cross-reactivity with human C5a. The antibodies are used to detect or quantify circulating C5a analogue or derivative, as well as to modify, e.g.

Abstract: Disclosed are polypeptide analogues of human C5a which are C5a receptor antagonists that exhibit substantially no analphylatoxin or agonist activity, and derivatives of the analogues, and dimeric forms of the analogues or derivatives. DNA molecules encoding the polypeptides and methods of making the analogues are also provided. Pharmaceutical formulations containing a C5a analogue, are used therapeutically in the treatment of C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an event which causes inflammation or aggravates an existing inflammatory condition, respectively. Further disclosed are antibodies specific to the C5a analogues, derivatives thereof, and dimers of the analogues and derivatives which exhibit substantially no cross-reactivity with human C5a. The antibodies are used to detect or quantify circulating C5a analogue or derivative, as well as to modify, e.g.

Abstract: Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA and of human u-PA, and mutants thereof in which at least one of the N-glycosylation sites is modified such that glycosylation cannot take place at these sites exhibit valuable pharmacological properties. The hybrid plasminogen activators are produced by recombinant DNA technology.

Abstract: Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA and of human u-PA, and mutants thereof in which at least one of the N-glycosylation sites is modified such that glycosylation cannot take place at these sites exhibit valuable pharmacological properties. The hybrid plasminogen activators are produced by recombinant DNA technology.

Abstract: In an electron beam apparatus corrections are made for vibrations and field disturbances which cause a lateral beam shift. A detector is arranged in an intermediate image near the beam path and a signal derived therefrom is used for controlling a beam deflection device. When a second beam deflection device is added, the undesired deflection in a scanning electron microscope can be distinguished from the deflection caused by the scanning.